| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 158: 59-63 (1991)
© 1991 The Royal College of Psychiatrists
CB Nemeroff, G Bissette, H Akil and M Fink
Department of Psychiatry and Pharmacology, Duke University Medical Center, Durham, North Carolina 27710.
The CSF concentrations of CRF, somatostatin and beta-endorphin were determined in nine patients who fulfilled DSM-III criteria for major depression with psychotic features. CSF samples were obtained at baseline in the depressed state, and again after a course of ECT. Concentrations of both CRF and beta-endorphin decreased after ECT, while the concentration of somatostatin increased, although the latter difference did not attain statistical significance. The increase in CSF concentrations of CRF and beta-endorphin in depressed patients is therefore seen to be state-dependent.
This article has been cited by other articles:
|
|
 |
|
  B. Binneman, D. Feltner, S. Kolluri, Y. Shi, R. Qiu, and T. Stiger A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH1 Antagonist) in the Treatment of Major Depression Am J Psychiatry, May 1, 2008; 165(5): 617 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Nemeroff Recent Findings in the Pathophysiology of Depression Focus, January 1, 2008; 6(1): 3 - 14. [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Gillespie and C. B. Nemeroff Hypercortisolemia and Depression Psychosom Med, May 1, 2005; 67(Supplement_1): S26 - S28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kaufman, B.-Z. Yang, H. Douglas-Palumberi, S. Houshyar, D. Lipschitz, J. H. Krystal, and J. Gelernter Social supports and serotonin transporter gene moderate depression in maltreated children PNAS, December 7, 2004; 101(49): 17316 - 17321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Merali, L. Du, P. Hrdina, M. Palkovits, G. Faludi, M. O. Poulter, and H. Anisman Dysregulation in the Suicide Brain: mRNA Expression of Corticotropin-Releasing Hormone Receptors and GABAA Receptor Subunits in Frontal Cortical Brain Region J. Neurosci., February 11, 2004; 24(6): 1478 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Gilmor, K. H. Skelton, C. B. Nemeroff, and M. J. Owens The Effects of Chronic Treatment with the Mood Stabilizers Valproic Acid and Lithium on Corticotropin-Releasing Factor Neuronal Systems J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Strome, G. H. T. Wheler, J. D. Higley, D. L. Loriaux, S. J. Suomi, and D. J. Doudet Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates PNAS, November 26, 2002; 99(24): 15749 - 15754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gully, M. Geslin, L. Serva, E. Fontaine, P. Roger, C. Lair, V. Darre, C. Marcy, P.-E. Rouby, J. Simiand, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 322 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heit, M. J. Owens, P. Plotsky, and C. B. Nemeroff {blacksquare} REVIEW : Corticotropin-releasing Factor, Stress, and Depression Neuroscientist, May 1, 1997; 3(3): 186 - 194. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
